Physician profile
Afsoon Karimi
NPI 1144299256
$3,569.46
in general payments reported to CMS, 2019-2025
23 companies · $753 in 2025
The $753 reported for 2025 was more than what 97% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111 · 2020: $91.52 · 2021: $526 · 2022: $650 · 2023: $760 · 2024: $677 · 2025: $753.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,190.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $675.04 | 2021-2025 | Breztri, Airsupra, Fasenra |
| Medtronic, INC. | $393.34 | 2023-2024 | Sonicision |
| Pfizer INC. | $358.39 | 2019-2025 | |
| Novo Nordisk INC | $354.45 | 2021-2023 | |
| Glaxosmithkline, LLC. | $350.31 | 2019-2025 | Pediarix, Bexsero, Shingrix |
| Merck Sharp & Dohme LLC | $244.07 | 2021-2025 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Bayer Healthcare Pharmaceuticals INC. | $210.20 | 2021-2022 | |
| Cranial Technologies, INC | $166.60 | 2019-2025 | Doc Band |
| Phathom Pharmaceuticals, INC. | $140.46 | 2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $122.35 | 2023 | Xarelto |
| Sanofi Pasteur INC. | $91.12 | 2022-2023 | |
| Abbvie INC. | $85.59 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $77.62 | 2025 | Neffy |
| Abbott Laboratories | $69.49 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.59 | 2020-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biomarin Pharmaceutical INC. | $34.93 | 2022-2025 | Voxzogo 1.2mg |
| Gilead Sciences, INC. | $28.08 | 2025 | |
| Renalytix Ai, INC. | $24.07 | 2022 | |
| Lilly USA, LLC | $23.01 | 2021 | |
| Cipher Pharmaceuticals US LLC | $22.92 | 2025 | Spinosad, Natroba |
| Kyowa Kirin, INC. | $22.04 | 2024 | Crysvita |
| Vbi Vaccine (Delaware) INC. | $21.16 | 2023 | Prehevbrio |
| Seqirus USA INC | $18.63 | 2024 | Flucelvax |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Afsoon Karimi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.